Meiji Seika Pharma Co., Ltd.: CORRECTING and REPLACING Meiji Seika Pharma: Promising Results of Phase I Clinical Trial of DMB-3115, a Proposed Ustekinumab Biosimilar, and Initiation of Phase III Clinical Trial in Patients With Plaque Psoriasis

(0)
First paragraph, third sentence of release dated May 20, 2021, should read: Those clinical trials are conducted in collaboration with Dong-A Socio Holdings (Headquarters: Seoul, Korea, CEO: JUNG Jae-Hun, "Dong-A"). (instead of Those clinical trials are conducted in collaboration with Dong-A Socio Holdings (Headquarters: Seoul, Korea, CEO: Jong Hyun Han, "Dong-A").).
The updated release reads:
MEIJI SEIKA PHARMA:
PROMISING RESULTS OF PHASE I CLINICAL TRIAL OF DMB-3115, A PROPOSED USTEKINUMAB BIOSIMILAR, AND INITIATION OF PHASE III CLINICAL TRIAL IN PATIENTS WITH PLAQUE PSORIASIS
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan, President and Representative Director: Daikichiro Kobayashi, "Meiji") today announced that the bioequivalence of DMB-3115, a proposed ustekinumab biosimilar, has been demonstrated in phase I clinical trial compared to the reference products marketed in Europe and the United States. Meiji also announced the initiation of phase III multi-regional clinical trial in patients with plaque psoriasis. Those clinical trials are conducted in collaboration with Dong-A Socio Holdings (Headquarters: Seoul, Korea, CEO: JUNG Jae-Hun, "Dong-A").

Related Keywords

Seoul ,Soult Ukpyolsi ,South Korea ,Japan ,Tokyo ,United States ,Daikichiro Kobayashi ,Kostenloser Wertpapierhandel ,Jong Hyun Han ,Business Development Dept ,Donga Socio Holdings Headquarters ,Meiji Seika Pharma Co Ltd ,Donga Socio Holdings ,Representative Director ,Product Acquisition ,Business Development ,Meiji ,Zuleika ,Dharma ,Kcorrecting ,Eplacing ,Romising ,Results ,Hase ,Linical ,Trial ,115 ,Roposed ,Bustekinumab ,Biosimilar ,Initiation ,Patients ,Ith ,Plaque ,Psoriasis ,சியோல் ,தெற்கு கொரியா ,ஜப்பான் ,டோக்கியோ ,ஒன்றுபட்டது மாநிலங்களில் ,வணிக வளர்ச்சி டெபிட் ,டோங்கா சமூக ஹோல்டிங்ஸ் ,பிரதிநிதி இயக்குனர் ,ப்ராடக்ட் கையகப்படுத்தல் ,வணிக வளர்ச்சி ,மேஜி ,ரியால் ,இத் ,